Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2,4-diamino-5-(6-methylveratryl)pyrimidine
1. 6981-18-6
2. Ormethoprim
3. Ormetorprim
4. 2,4-diamino-5-(6-methylveratryl)pyrimidine
5. Ro 5-9754
6. Component Of Rofenaid
7. Ormetroprim
8. 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine
9. 2,4-pyrimidinediamine, 5-[(4,5-dimethoxy-2-methylphenyl)methyl]-
10. 5-(4,5-dimethoxy-2-methylbenzyl)-2,4-diaminopyrimidine
11. 5-(4,5-dimethoxy-2-methylbenzyl)pyrimidine-2,4-diamine
12. Nsc-95072
13. M3efs94984
14. Nsc95072
15. Ro-59754
16. Ncgc00167523-01
17. Ormetoprim 100 Microg/ml In Acetonitrile
18. Ro-5-9754
19. 2,4-pyrimidinediamine, 5-((4,5-dimethoxy-2-methylphenyl)methyl)-
20. Dsstox_cid_26689
21. Dsstox_rid_81823
22. Dsstox_gsid_46689
23. Ormetoprima
24. Ormetoprime
25. Ormetoprimum
26. 5-[(4,5-dimethoxy-2-methyl-phenyl)methyl]pyrimidine-2,4-diamine
27. Smr000466374
28. Cas-6981-18-6
29. Ormetoprim [usan:inn]
30. Nsc 95072
31. Ormetoprime [inn-french]
32. Ormetoprimum [inn-latin]
33. Ormetoprima [inn-spanish]
34. Unii-m3efs94984
35. Einecs 230-246-6
36. Ormetoprim [inn]
37. Ormetoprim [jan]
38. Ormetoprim (usan/inn)
39. Ormetoprim [usan]
40. Ormetoprim [mart.]
41. Pyrimidine, 2,4-diamino-5-(6-methylveratryl)-
42. Nciopen2_006334
43. Schembl93810
44. Zinc562
45. Mls000759503
46. Mls001424067
47. Chembl494760
48. Ormetoprim [green Book]
49. 2,4-diamino-5-(4,5-dimethoxy-2-methylbenzyl)pyrimidin
50. Dtxsid1046689
51. Chebi:94553
52. Cv564
53. Hms2051k20
54. Hms3393k20
55. Bcp06018
56. Tox21_112520
57. Bdbm50413401
58. Mfcd00057747
59. S5290
60. Akos015917221
61. Tox21_112520_1
62. Ccg-100900
63. Nc00150
64. Sb60507
65. Ncgc00167523-02
66. Ncgc00167523-03
67. As-71719
68. Bo164180
69. Db-055351
70. Hy-121466
71. Sd-051044
72. Am20041036
73. Cs-0082144
74. Ft-0630358
75. O0424
76. Pyrimidine,4-diamino-5-(6-methylveratryl)-
77. D05273
78. T72844
79. 2, 5-[(4,5-dimethoxy-2-methylphenyl)methyl]-
80. Ab00639990-08
81. 981o186
82. A836658
83. W-104583
84. Q27166391
85. 2,4-diamino-5-(4,5-dimethoxy-2-methylbenzyl)pyrimidine
86. 5-(4,5-dimethoxy-2-methylbenzyl)-2,4-pyrimidinediamine
87. 2,4-diamino-5-(4,5-dimethoxy-2-methylbenzyl) Pyrimidine
88. 5-(4,5-dimethoxy-2-methyl-benzyl)-pyrimidine-2,4-diamine
| Molecular Weight | 274.32 g/mol |
|---|---|
| Molecular Formula | C14H18N4O2 |
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 274.14297583 g/mol |
| Monoisotopic Mass | 274.14297583 g/mol |
| Topological Polar Surface Area | 96.3 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 305 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Market Place
ABOUT THIS PAGE
A Ormetoprim manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ormetoprim, including repackagers and relabelers. The FDA regulates Ormetoprim manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ormetoprim API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ormetoprim supplier is an individual or a company that provides Ormetoprim active pharmaceutical ingredient (API) or Ormetoprim finished formulations upon request. The Ormetoprim suppliers may include Ormetoprim API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ormetoprim as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ormetoprim API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ormetoprim as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ormetoprim and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ormetoprim NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ormetoprim suppliers with NDC on PharmaCompass.
Ormetoprim Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ormetoprim GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ormetoprim GMP manufacturer or Ormetoprim GMP API supplier for your needs.
A Ormetoprim CoA (Certificate of Analysis) is a formal document that attests to Ormetoprim's compliance with Ormetoprim specifications and serves as a tool for batch-level quality control.
Ormetoprim CoA mostly includes findings from lab analyses of a specific batch. For each Ormetoprim CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ormetoprim may be tested according to a variety of international standards, such as European Pharmacopoeia (Ormetoprim EP), Ormetoprim JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ormetoprim USP).
LOOKING FOR A SUPPLIER?
